Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

pozelimab

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

Preparing for ASH 2025: Pharma’s role in hematology innovation

As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

Inizio

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

regeneron headquarters

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

- PMLiVE

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease

- PMLiVE

J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma

The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

- PMLiVE

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

- PMLiVE

Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study

Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links